Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature
- Resource Type
- article
- Authors
- Oliver E. Yausep; Raksheeth Agarwal; Rifqha Aulina; Anthony E. Wijaya; Ilonka Amaia; Addina W. Moekti; Ikhwan Rinaldi; Agus Rizal A. H. Hamid
- Source
- Clinical Case Reports, Vol 7, Iss 8, Pp 1585-1590 (2019)
- Subject
- abiraterone
lymphocyte
metastatic Castration‐Resistant Prostate Cancer
platelet
platelet to lymphocyte ratio
prostate cancer
Medicine
Medicine (General)
R5-920
- Language
- English
- ISSN
- 2050-0904
Abstract Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration‐resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and establish a definite cutoff point.